substance p has been researched along with Depressive Disorder in 29 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (20.69) | 18.7374 |
| 1990's | 5 (17.24) | 18.2507 |
| 2000's | 16 (55.17) | 29.6817 |
| 2010's | 2 (6.90) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Demuth, HU; Heiser, U; Hoffmann, T; Kaestner, F; Manhart, S; Rahfeld, JU; Rothermundt, M; Stiller, H; von Hörsten, S; Wagner, L; Wolf, R | 1 |
| Sümegi, A | 1 |
| Bilkei-Gorzó, A; Frisch, P; Rácz, I; Zimmer, A | 1 |
| Mantyh, PW | 1 |
| Hargreaves, R | 1 |
| Krishnan, R; Ranga, K | 1 |
| Stahl, SM | 2 |
| Santarelli, L; Saxe, MD | 1 |
| Holden, C | 1 |
| Adell, A | 1 |
| Learner, F | 1 |
| Chandra, P; Cowen, J; Hafizi, S | 1 |
| Benton, T; Douglas, SD; Dubé, B; Evans, DL; Gettes, DR; Lai, JP; Lynch, KG; Metzger, D; Tustin, NB | 1 |
| Thase, ME | 1 |
| Adachi, S; Kaiya, H; Moriuchi, I; Namba, M; Tamura, Y; Tanaka, M; Yanaihara, C; Yanaihara, N; Yoshida, H | 1 |
| Balfe, A; Maguire, J; Powell, D; Skrabanek, P; Webb, M | 1 |
| Shibuya, H | 1 |
| Heikkilä, L; Le Grevés, P; Nyberg, F; Rimón, R; Salmela, L; Terenius, L | 1 |
| Carlson, EJ; Carman, J; Cascieri, MA; Chicchi, GG; Cutler, N; Feighner, J; Hale, JJ; Hargreaves, RJ; Harrison, T; Hefti, F; Hewson, L; Hill, RG; Kramer, MS; Liu, G; MacCoss, M; Mills, SG; Reines, SA; Rupniak, NM; Sadowski, S; Scolnick, EM; Shrivastava, R; Smith, D; Snavely, D; Sramek, JJ; Swain, CJ; Williams, AR; Wyatt-Knowles, E | 1 |
| Wahlestedt, C | 1 |
| Nutt, D | 1 |
| Enserink, M | 1 |
| Matsubayashi, H | 1 |
| Argyropoulos, SV; Nutt, DJ | 1 |
| Rupniak, NM | 1 |
| Berrettini, WH; Gershon, ES; Nurnberger, JI; Post, RM; Rubinow, DR; Simmons-Alling, S | 1 |
| Bertilsson, L; Brodin, E; Mårtensson, B; Nyberg, S; Toresson, G | 1 |
8 review(s) available for substance p and Depressive Disorder
| Article | Year |
|---|---|
[Domino principle--monoamines in bottom-view].
Topics: Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents; Biogenic Monoamines; Corticotropin-Releasing Hormone; Depression; Depressive Disorder; Dopamine Uptake Inhibitors; Galanin; Humans; Locus Coeruleus; Neuropeptide Y; Neuropeptides; Neurotransmitter Agents; Norepinephrine; Raphe Nuclei; Selective Serotonin Reuptake Inhibitors; Serotonin; Substance P | 2008 |
Neurobiology of substance P and the NK1 receptor.
Topics: Affect; Animals; Antidepressive Agents; Anxiety Disorders; Brain; Cell Death; Cells, Cultured; Depressive Disorder; Humans; Immunotoxins; Killer Cells, Natural; Mice; Models, Animal; Rats; Receptors, Immunologic; Receptors, Neurokinin-1; Ribosome Inactivating Proteins, Type 1; Saporins; Spinal Cord; Substance P | 2002 |
Imaging substance P receptors (NK1) in the living human brain using positron emission tomography.
Topics: Animals; Aprepitant; Autoradiography; Brain; Brain Mapping; Depressive Disorder; Dose-Response Relationship, Drug; Drug Administration Schedule; Guinea Pigs; Humans; Iodine Radioisotopes; Macaca mulatta; Morpholines; Neurokinin-1 Receptor Antagonists; Receptors, Neurokinin-1; Substance P; Tomography, Emission-Computed | 2002 |
Substance P antagonists: meet the new drugs, same as the old drugs? Insights from transgenic animal models.
Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents; Anxiety Disorders; Brain; Clinical Trials as Topic; Depressive Disorder; Disease Models, Animal; Drug Evaluation, Preclinical; Drugs, Investigational; Humans; Mice; Mice, Transgenic; Receptors, Neurokinin-1; Substance P | 2003 |
Antidepressant properties of substance P antagonists: relationship to monoaminergic mechanisms?
Topics: Animals; Antidepressive Agents; Biogenic Monoamines; Brain; Brain Chemistry; Depression; Depressive Disorder; Humans; Neurokinin-1 Receptor Antagonists; Neurons; Receptors, Neurokinin-1; Serotonin; Substance P; Tissue Distribution | 2004 |
[Neuropeptides and mental disorders].
Topics: Aged; Alzheimer Disease; Animals; Brain; Cholecystokinin; Depressive Disorder; Endorphins; Female; Humans; Male; Mental Disorders; Middle Aged; Nerve Tissue Proteins; Neurotransmitter Agents; Schizophrenia; Substance P; Vasopressins | 1983 |
Substance P antagonists: novel agents in the treatment of depression.
Topics: Animals; Antidepressive Agents; Depressive Disorder; Humans; Neuropeptides; Substance P | 2000 |
Elucidating the antidepressant actions of substance P (NK1 receptor) antagonists.
Topics: Animals; Antidepressive Agents; Aprepitant; Clinical Trials as Topic; Depressive Disorder; Drug Evaluation, Preclinical; Humans; Morpholines; Neurokinin-1 Receptor Antagonists; Stress, Physiological; Substance P; Treatment Outcome | 2002 |
4 trial(s) available for substance p and Depressive Disorder
| Article | Year |
|---|---|
Clinical experience with substance P receptor (NK1) antagonists in depression.
Topics: Antidepressive Agents; Anxiety Disorders; Aprepitant; Depressive Disorder; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Ethers; Female; Humans; Hydrocarbons, Fluorinated; Male; Morpholines; Neurokinin-1 Receptor Antagonists; Paroxetine; Placebos; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Substance P; Treatment Outcome | 2002 |
Selective serotonin reuptake inhibitor and substance P antagonist enhancement of natural killer cell innate immunity in human immunodeficiency virus/acquired immunodeficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Adult; Biphenyl Compounds; Citalopram; Depressive Disorder; Depressive Disorder, Major; Female; Glucocorticoids; HIV Seropositivity; Hormone Antagonists; Humans; Immunity, Innate; Killer Cells, Natural; Lymphocyte Count; Middle Aged; Mifepristone; Personality Inventory; Selective Serotonin Reuptake Inhibitors; Substance P; T-Lymphocytes, Cytotoxic; Viral Load | 2008 |
Distinct mechanism for antidepressant activity by blockade of central substance P receptors.
Topics: Adolescent; Adult; Aged; Amygdala; Animals; Antidepressive Agents, Second-Generation; Aprepitant; Behavior, Animal; Brain; Depressive Disorder; Female; Gerbillinae; Guinea Pigs; Humans; Male; Middle Aged; Morpholines; Neurokinin-1 Receptor Antagonists; Norepinephrine; Paroxetine; Receptors, Neurokinin-1; Serotonin; Stress, Psychological; Substance P; Vocalization, Animal | 1998 |
Substance-P antagonists: a new treatment for depression?
Topics: Antidepressive Agents, Second-Generation; Anxiety Disorders; Aprepitant; Depressive Disorder; Double-Blind Method; Humans; Morpholines; Paroxetine; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Substance P | 1998 |
17 other study(ies) available for substance p and Depressive Disorder
| Article | Year |
|---|---|
Identifying neuropeptide Y (NPY) as the main stress-related substrate of dipeptidyl peptidase 4 (DPP4) in blood circulation.
Topics: Adult; Animals; Antidepressive Agents; Depressive Disorder; Dipeptidyl Peptidase 4; Endothelium; Female; Humans; Hydrolysis; Isoenzymes; Male; Middle Aged; Neuropeptide Y; Orexins; Pituitary Adenylate Cyclase-Activating Polypeptide; Protein Processing, Post-Translational; Proteolysis; Rats; Stress, Psychological; Substance P | 2016 |
Modulation of the CRH system by substance P/NKA in an animal model of depression.
Topics: Adrenocorticotropic Hormone; Animals; Carrier Proteins; Cerebral Cortex; Depressive Disorder; Disease Models, Animal; Feeding Behavior; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Neurokinin A; Olfactory Bulb; Paraventricular Hypothalamic Nucleus; Receptors, Corticotropin-Releasing Hormone; Saccharin; Substance P | 2010 |
The ups and downs of novel antiemetic drugs, part 1: substance P, 5-HT, and the neuropharmacology of vomiting.
Topics: Antiemetics; Antineoplastic Agents; Aprepitant; Area Postrema; Brain Stem; Depressive Disorder; Humans; Morpholines; Receptors, Neurokinin-1; Serotonin; Solitary Nucleus; Stress Disorders, Traumatic; Substance P; Vomiting | 2003 |
The ups and downs of novel antiemetic drugs, part 2: an illustration.
Topics: Antiemetics; Brain Stem; Depressive Disorder; Humans; Models, Neurological; Neurokinin-1 Receptor Antagonists; Receptors, Serotonin; Receptors, Serotonin, 5-HT3; Serotonin; Stress Disorders, Traumatic; Substance P; Vomiting | 2003 |
Future brightening for depression treatments.
Topics: Adult; Animals; Antidepressive Agents; Brain; Child; Clinical Trials as Topic; Corticotropin-Releasing Hormone; Depression; Depressive Disorder; Dopamine Agents; Electric Stimulation Therapy; Electroconvulsive Therapy; Humans; Magnetics; Neurons; Phosphodiesterase Inhibitors; Psychotherapy; Receptors, N-Methyl-D-Aspartate; Stress, Psychological; Substance P | 2003 |
The future of antidepressants.
Topics: Antidepressive Agents; Antidepressive Agents, Tricyclic; Clinical Trials as Topic; Depressive Disorder; Humans; Monoamine Oxidase Inhibitors; Risk Assessment; Selective Serotonin Reuptake Inhibitors; Substance P | 2005 |
Neurokinin-1 receptor antagonists as novel antidepressants: trials and tribulations.
Topics: Animals; Antidepressive Agents; Aprepitant; Clinical Trials as Topic; Depressive Disorder; Drug Design; Humans; Models, Animal; Morpholines; Neurokinin-1 Receptor Antagonists; Substance P | 2007 |
Molecules that mediate mood.
Topics: Adaptation, Psychological; Animals; Antidepressive Agents; Depressive Disorder; Gene Expression Regulation; Helplessness, Learned; Humans; Mice; Neurons; Proto-Oncogene Proteins c-fos; Stress, Psychological; Substance P | 2007 |
Substance P-like immunoreactivity in plasma of psychotic patients and effects of neuroleptics and electroconvulsive therapy.
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Chlorpromazine; Depressive Disorder; Electroconvulsive Therapy; Female; Humans; Male; Middle Aged; Neurocognitive Disorders; Neurotic Disorders; Psychotic Disorders; Schizophrenia; Substance P | 1981 |
Electroconvulsive therapy (ECT) increases plasma growth hormone, prolactin, luteinising hormone and follicle-stimulating hormone but not thyrotropin or substance P.
Topics: Adult; Aged; Depressive Disorder; Electroconvulsive Therapy; Female; Follicle Stimulating Hormone; Growth Hormone; Humans; Kinetics; Luteinizing Hormone; Male; Middle Aged; Prolactin; Radioimmunoassay; Substance P | 1981 |
Elevation of substance P-like peptides in the CSF of psychiatric patients.
Topics: Adult; Depressive Disorder; Female; Humans; Intercellular Signaling Peptides and Proteins; Male; Middle Aged; Peptide Fragments; Peptides; Radioimmunoassay; Schizophrenia; Substance P | 1984 |
Reward for persistence in substance P research.
Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Aprepitant; Brain; Clinical Trials, Phase II as Topic; Depressive Disorder; Humans; Morpholines; Neurokinin-1 Receptor Antagonists; Substance P | 1998 |
Can the placebo be the cure?
Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Aprepitant; Depressive Disorder; Double-Blind Method; Humans; Meta-Analysis as Topic; Monoamine Oxidase Inhibitors; Morpholines; Placebos; Psychopharmacology; Randomized Controlled Trials as Topic; Research Design; Selective Serotonin Reuptake Inhibitors; Substance P | 1999 |
[Can substance P antagonists constitute a new axis for antidepressants?].
Topics: Animals; Antidepressive Agents; Depressive Disorder; Humans; Substance P | 1999 |
Depression. Five new treatments.
Topics: Antidepressive Agents; Depression; Depressive Disorder; Electric Stimulation Therapy; Humans; Hydrocortisone; Magnetics; Morpholines; Reboxetine; Substance P; Vagus Nerve | 2000 |
CSF substance P immunoreactivity in affective disorders.
Topics: Bipolar Disorder; Chromatography, Gel; Depressive Disorder; Humans; Radioimmunoassay; Substance P | 1985 |
Fluoxetine treatment of depression. Clinical effects, drug concentrations and monoamine metabolites and N-terminally extended substance P in cerebrospinal fluid.
Topics: Adult; Aged; Depressive Disorder; Female; Fluoxetine; Glycols; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Male; Methoxyhydroxyphenylglycol; Middle Aged; Peptide Fragments; Substance P | 1989 |